{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:51:45Z","timestamp":1781869905622,"version":"3.54.5"},"reference-count":26,"publisher":"FapUNIFESP (SciELO)","issue":"3","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>SUMMARY  OBJECTIVE: The aim of this study was to evaluate the impact of sodium-glucose cotransporter-2 inhibitors on haematological parameters and other clinical markers in this patient population.  METHODS: We retrospectively analyzed the medical records of 150 diabetic patients with chronic kidney disease who initiated sodium-glucose cotransporter-2 inhibitor therapy, comparing their baseline and 3-month post-treatment laboratory and clinical data.  RESULTS: Following 3 months of treatment with sodium-glucose cotransporter-2 inhibitors, mean haemoglobin and haematocrit levels significantly increased, even in patients with an estimated glomerular filtration rate below 60 mL\/min\/1.73 m2. This therapy also led to significant reductions in the spot urine albumin-to-creatinine ratio, as well as in both systolic and diastolic blood pressure.  CONCLUSION: Sodium-glucose cotransporter-2 inhibitor therapy was associated with significant increases in haemoglobin and haematocrit levels in diabetic patients with chronic kidney disease. These findings suggest that sodium-glucose cotransporter-2 inhibitors may represent a potential area requiring further investigation for the treatment of anaemia associated with diabetic chronic kidney disease.<\/jats:p>","DOI":"10.1590\/1806-9282.20251460","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:01:44Z","timestamp":1781866904000},"source":"Crossref","is-referenced-by-count":0,"title":["The effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease"],"prefix":"10.1590","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4680-7435","authenticated-orcid":false,"given":"S\u00fcleyman","family":"Karak\u00f6se","sequence":"first","affiliation":[{"name":"University of Health Science,  Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-1231","authenticated-orcid":false,"given":"Beyza","family":"Do\u011fan","sequence":"additional","affiliation":[{"name":"University of Health Science,  Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-9710","authenticated-orcid":false,"given":"Fatih","family":"Erg\u00fcl","sequence":"additional","affiliation":[{"name":"University of Health Science,  Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1646-2811","authenticated-orcid":false,"given":"\u0130brahim","family":"G\u00fcney","sequence":"additional","affiliation":[{"name":"University of Health Science,  Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2026]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes.","volume":"24","author":"Afkarian M","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"ref2","doi-asserted-by":"crossref","first-page":"s55","DOI":"10.1590\/1806-9282.66.s1.55","article-title":"Anemia in chronic kidney disease.","volume":"66","author":"Hazin MAA","year":"2020","journal-title":"Rev Assoc Med Bras (1992)."},{"issue":"22","key":"ref3","doi-asserted-by":"crossref","first-page":"13749","DOI":"10.3390\/ijms232213749","article-title":"Sodium-glucose cotransporter-2 inhibitors-miracle drugs for the treatment of chronic kidney disease irrespective of the diabetes status: lessons from the dedicated kidney disease-focused CREDENCE and DAPA-CKD trials.","volume":"23","author":"Gohda T","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease.","volume":"21","author":"Maruyama T","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"17","key":"ref5","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects.","volume":"139","author":"Sano M","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40199-021-00417-5","article-title":"Beneficial effects of empagliflozin on hematocrit levels in a patient with severe anemia.","volume":"29","author":"Budzianowski J","year":"2021","journal-title":"Daru"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"EVIDoa2300049","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and anemia in patients with chronic kidney disease.","volume":"2","author":"Koshino A","year":"2023","journal-title":"NEJM Evid"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"e240946","DOI":"10.1001\/jamanetworkopen.2024.0946","article-title":"Use of SGLT2 inhibitors vs GLP-1 RAs and anemia in patients with diabetes and CKD.","volume":"7","author":"Hu JC","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"(Suppl 4S)","key":"ref9","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"15","key":"ref10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink HJL","year":"2020","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fimmu.2015.00340","article-title":"Cellular and molecular mechanisms of chronic kidney disease with diabetes mellitus 20. and cardiovascular diseases as its comorbidities.","volume":"6","author":"Gajjala PR","year":"2015","journal-title":"Front Immunol"},{"key":"ref12","series-title":"Kidney disease in diabetes in America.","author":"Meda E","year":"2018","edition":"3rd ed"},{"issue":"2","key":"ref13","first-page":"117","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/biomedicines11020279","article-title":"SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease.","volume":"11","author":"Podest\u00e0 MA","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects.","volume":"142","author":"Griffin M","year":"2020","journal-title":"Circulation"},{"issue":"228","key":"ref16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial.","volume":"228","author":"Jensen J","year":"2020","journal-title":"Am Heart J"},{"issue":"21","key":"ref17","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray JJV","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"ref18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer M","year":"2020","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function.","volume":"83","author":"Vallon V","year":"2021","journal-title":"Annu Rev Physiol"},{"issue":"24","key":"ref20","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic V","year":"2019","journal-title":"N Engl J Med."},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.","volume":"15","author":"Lambers Heerspink HJ","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.","volume":"319","author":"Onishi A","year":"2020","journal-title":"Am J Physiol Renal Physiol."},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease.","volume":"141","author":"Mazer CD","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial.","volume":"41","author":"Inzucchi SE","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/ndt\/gfae032","article-title":"How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.","volume":"39","author":"Wanner C","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000531084","article-title":"Mechanistic and clinical comparison of the erythropoietic effects of SGLT2 inhibitors and prolyl hydroxylase inhibitors in patients with chronic kidney disease and renal anemia.","volume":"55","author":"Packer M","year":"2024","journal-title":"Am J Nephrol"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0104-42302026000302217&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:01:48Z","timestamp":1781866908000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302026000302217&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"alternative-id":["S0104-42302026000302217"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.20251460","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e20251460"}}